Currently, intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF), known as anti-VEGF therapy, has replaced photodynamic therapy (PDT) as the first-line treatment for neovascular age-related macular degeneration (nAMD) and has demonstrated effective results in treating active PCV [6–8] Several clinical trials have shown that anti-VEGF monotherapy, including aflibercept and ranibizumab, yields favorable visual outcomes for PCV compared with PDT or combination therapy [9–12]. The gene discussed is VEGFA; the disease is wet macular degeneration.